Figure 2.

lncRNA ZNF649-AS1 Is Associated with Poor Response to Trastuzumab Treatment

(A) Quantitative real-time PCR showed that ZNF649-AS1 was significantly upregulated in 30 trastuzumab-resistant tissues compared with 30 responding tissues. (B) Serum ZNF649-AS1 was determined in 45 resistant and 45 responding patients. (C) Statistical analysis showed that the proportion of responding patients in the high-ZNF649-AS1 group was significantly lower in than that in low-ZNF649-AS1 group. (D) ROC curve was established to evaluate the potential of ZNF649-AS1 expression in discriminating responding and non-responding patients. (E) Kaplan-Meier survival analysis proved that high ZNF649-AS1 expression is associated with poorer overall survival (upper panel) and progressive-free survival (lower panel).